|DATSCAN™ Now Available at Kennedy to Help Physicians Differienate Parkinsonian Syndromes from Essential Tremors|
|Thursday, April 18, 2013|
Kennedy University Hospital is now offering DaTscan™, the first FDA-approved radiopharmaceutical adjunct imaging agent to help physicians evaluate patients with suspected parkinsonian syndromes (PS), such as Parkinson’s disease (PD).
DaTscan gives physicians additional diagnostic capability that may help lead to timely and appropriate diagnosis and treatment. An accurate diagnosis for patients with neurodegenerative movement disorders, such as PD, can take up to six years. PD, which currently affects one million people in the US, is one of several types of PS.
“This new imaging agent is a step in the right direction for timely and accurate diagnosis for patients with parkinsonian syndromes, such as Parkinson’s disease,” said Dr. Locke Barber, D.O., Chief of Medical Imaging at Kennedy. “The challenge for physicians is how to differentiate parkinsonian syndromes from other conditions that mimic it, such as essential tremor. While the symptoms are similar, treatment and management greatly differ. Having another diagnostic tool to help rule out one of these conditions is tremendously helpful in reaching an appropriate and timely diagnosis for patients.”
PS occurs when the brain does not get enough dopamine to perform certain functions. This affects the ability of the brain to control movement and other muscle functions. DaTscan is an adjunct to other diagnostic evaluations that help differentiate essential tremor (ET) – a common movement disorder – from tremors due to PS. In the United States, 50,000 to 60,000 new cases of PD are diagnosed each year. timely and correct diagnosis can help patients and their families overcome the fears and frustrations associated with the process of getting an accurate diagnosis so they can move on with their lives. To learn more about DaTscan, visit www.datscan.com or call 856-582-2769 or 856-346-7999.